Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.
Cell biology and toxicology January 29, 2025 Xiaoming Ji, Zhimin Huang, Chenming Zhou et al. 6 citations
Esketamine, a new antidepressant, reduces depressive-like behavior in mice with neuropathic pain by boosting levels of the m6A methyltransferase METTL3 and the AMPA receptor GluA1 subunit. Esketamine activates METTL3, which binds to GluA1 mRNA and promotes m6A modification, enhancing GluA1 expression at synapses. This mechanism offers new insights into esketamine's potential applications and therapeutic avenues for neuropathic pain and depressive behavior.